Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Experimental Drug Prevents Ischemia in Mouse Muscular Dystrophy Model

By BiotechDaily International staff writers
Posted on 22 Nov 2012
Treating mice with a form of muscular dystrophy that closely mimics human Duchenne muscular dystrophy (DMD) with the experimental drug HCT 1026 restored normal blood flow to muscles stressed by a hormone-induced exercise regimen.

The dystrophin deficiency that characterizes DMD causes loss of the neuronal enzyme nitric oxide synthase from the sarcolemma, producing functional ischemia when the muscles are exercised. Investigators at Cedars-Sinai Heart Institute (Los Angeles, CA, USA) asked whether functional muscle ischemia could be eliminated and normal blood flow regulation restored by treatment with an exogenous nitric oxide (NO)-donating drug.

The drug under evaluation was HCT 1026, a NO-donating nonsteroidal anti-inflammatory agent that had previously been shown to slow progression of DMD in the mdx mouse muscular dystrophy model.

In the current study, beginning at eight weeks of age, mdx mice were fed a standard diet supplemented with 1% soybean oil alone or in combination with a low or high dose of HCT 1026. After one month of treatment, vasoconstrictor responses to intra-arterial norepinephrine (NE) were compared in resting and contracting hindlimbs.

Results published in the November 5, 2012, online edition of the journal PLOS ONE revealed that in untreated mdx mice, the usual effect of muscle contraction to attenuate NE-mediated vasoconstriction was impaired, resulting in functional ischemia. This NE-induced functional ischemia was unaffected by low dose HCT 1026 but was alleviated by the high dose of the drug. The beneficial effect of high dose HCT 1026 was maintained with treatment up to three months.

"There is an urgent unmet need for effective therapeutic options for this devastating disease," said senior author Dr. Ronald G. Victor, professor of cardiology at Cedars-Sinai Heart Institute. "If we can improve blood flow in muscular dystrophy patients, we may be able to preserve some muscle function over a longer period of time."

The authors stressed that they did not expect these novel nitric oxide-donating compounds to cure DMD, but did hope that the improved blood flow that they induced could reduce muscle fatigue and injury, allowing patients to be more active while slowing down the loss of vital muscle tissue.

Related Links:
Cedars-Sinai Heart Institute




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.